Dr. Tasian and his research team use an epidemiologic framework, including randomized trials and multi-institutional observational studies, to examine the etiology of kidney stone disease and the comparative effectiveness of surgical interventions. He also employs machine learning of complex data to improve diagnosis, risk stratification, and prediction of treatment response for children and adults with benign urologic disease.
Dr. Oliver investigates the mechanisms governing T cell activation and protective immunity. Her goal is to define mechanisms that, when dysregulated, result in autoimmunity or allergic disorders like asthma.
The office of the Colket Chair provides leadership in synergizing interprofessional research between CHOP and PENN Nursing and generates knowledge that supports patient and family healing, their healthcare experience, and clinical outcomes.
The Mitochondrial Medicine Research Laboratory investigates the genetic etiologies, pathophysiologic mechanisms, and therapeutic targets of mitochondrial disease. The lab applies state-of-the-art technologies and approaches in diverse animals (C. elegans worms, D. rerio zebrafish, M. musculus mice), human cells, and patients to cross-validate key translational insights that will enable precision diagnosis, monitoring, and therapeutic management of primary and secondary mitochondrial diseases.
The Camire Lab is interested in understanding the components of the blood coagulation system, how they interface with activated cells, and how disturbances in their function lead to bleeding and thrombosis. The lab is also interested in developing novel therapeutic approaches (protein, gene-based, small molecule) to mitigate these events which are major causes of morbidity and mortality worldwide.
The Krantz lab focuses on identifying molecular etiologies of multisystem developmental diagnoses, structural birth defects, and intellectual disability. Using cellular and animal models, the investigators study newly identified genes towards identification of therapeutic targets. The lab is at the forefront of adapting new genomic technologies to the clinical setting and studying the impact on the clinicians and families involved.